179543-93-2 Usage
Uses
Used in Pharmaceutical Applications:
(2,4-DIMETHOXY-PHENYL)-HYDRAZINE is used as an intermediate in the synthesis of pharmaceutical compounds for its potential therapeutic properties.
Used in Anti-Tuberculosis Applications:
(2,4-DIMETHOXY-PHENYL)-HYDRAZINE is being studied for its potential as an anti-tuberculosis agent, indicating its use in the development of treatments for tuberculosis.
Used in Cancer Therapy Research:
(2,4-DIMETHOXY-PHENYL)-HYDRAZINE is being investigated for its possible use in cancer therapy, suggesting its application in the development of cancer treatment options.
Used in Organic Synthesis and Chemical Research:
Due to its unique structure and reactivity, (2,4-DIMETHOXY-PHENYL)-HYDRAZINE may also have applications in the field of organic synthesis and chemical research, serving as a valuable compound for further exploration and development.
Check Digit Verification of cas no
The CAS Registry Mumber 179543-93-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,5,4 and 3 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 179543-93:
(8*1)+(7*7)+(6*9)+(5*5)+(4*4)+(3*3)+(2*9)+(1*3)=182
182 % 10 = 2
So 179543-93-2 is a valid CAS Registry Number.
179543-93-2Relevant academic research and scientific papers
ENHANCERS OF PROTEIN DEGRADATION
-
Page/Page column 55, (2011/04/13)
The present invention relates to compounds suitable for modulating huntingtin protein processing and useful for treating or preventing huntingtin-related disorders. The invention provides pharmaceutical compositions comprising said compounds and methods of syntheses thereof.
Design and synthesis of new orally active inhibitors of human neutrophil elastase
Ohmoto, Kazuyuki,Okuma, Motohiro,Yamamoto, Tetsuya,Kijima, Hideomi,Sekioka, Tomohiko,Kitagawa, Kanji,Yamamoto, Shigeki,Tanaka, Kenji,Kawabata, Kazuhito,Sakata, Atsushi,Imawaka, Haruo,Nakai, Hisao,Toda, Masaaki
, p. 1307 - 1323 (2007/10/03)
To identify new orally active inhibitors, further modification of 1 (ONO-6818) was performed. Peptidic derivatives 4b, 4c and 4n showed more potent inhibitory activity than nonpeptidic derivatives 3a-c. As a result, a series of peptidic inhibitors, 4a-s a
